Journal of Hepatology
Volume 49, Issue 5 , Pages 688-694 , November 2008

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection

  • Andrej Potthoff

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany
    • Both authors contributed equally.
    • ,
  • Heiner Wedemeyer

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany
    • Both authors contributed equally.
    • ,
  • Wulf O. Boecher

      Affiliations

    • I. Medizinische Klinik und Poliklinik, Johannes Gutenberg Universität, Langenbeckstr. 1, 55131 Mainz, Germany
    • ,
  • Thomas Berg

      Affiliations

    • Department of Gastroenterology and Hepatology, Universitätsklinik Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    • ,
  • Stefan Zeuzem

      Affiliations

    • Department of Gastroenterology, Hepatology, Nutritial Medicine and Pneumology, Klinikum der Johann-Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
    • ,
  • Joachim Arnold

      Affiliations

    • II Medizinische Klinik, Diakoniekrankenhaus Rotenburg (Wümme), Elise-Averdieck-Strasse 17, 27356 Rotenburg (Wümme), Germany
    • ,
  • Ulrich Spengler

      Affiliations

    • Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
    • ,
  • Kurt Gruengreiff

      Affiliations

    • Gastroenterologische Praxis, Heydeckstr. 9, 39104 Magdeburg, Germany
    • ,
  • Thomas Kaeser

      Affiliations

    • Gastroenterologische Praxis, Marktplatz 14, 72250 Freudenstadt, Germany
    • ,
  • Marcus Schuchmann

      Affiliations

    • I. Medizinische Klinik und Poliklinik, Johannes Gutenberg Universität, Langenbeckstr. 1, 55131 Mainz, Germany
    • ,
  • Alexandra Bergk

      Affiliations

    • Department of Gastroenterology and Hepatology, Universitätsklinik Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    • ,
  • Nicole Forestier

      Affiliations

    • Department of Gastroenterology, Hepatology, Nutritial Medicine and Pneumology, Klinikum der Johann-Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
    • ,
  • Katja Deterding

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany
    • ,
  • Michael P. Manns

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 511 532 3305; fax: +49 511 532 4896.
    • ,
  • Christian Trautwein

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany
    • Medizinische Klinik III, Universitätsklinikum Aachen, Pauwelstrasse 30, 52074 Aachen, Germany
    • ,
  • for the Hep-Net B/C Co-infection Study Group

Received 20 January 2008 ,Revised 4 March 2008 ,Accepted 25 March 2008.

References 

  1. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024–1029
  2. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology. 2002;36:1285–1291
  3. Lee LP, Dai CY, Chuang WL, Chang WY, Hou NJ, Hsieh MY, et al. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol. 2007;22:515–517
  4. Benvegnù L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994;74:2442–2448
  5. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer. 1999;85:2132–2137
  6. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006;368:938–945
  7. Fattovich G, Tagger A, Brollo L, Giustina G, Pontisso P, Realdi G, et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis. 1991;163:400–402
  8. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis. 1992;165:831–834
  9. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28:27–33
  10. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529–1533
  11. Liaw YF, Chien RN, Lin SM, Yeh CT, Tsai SL, Sheen IS, et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res. 1997;17:449–452
  12. Yalcin K, Degertekin H, Alp MN, Tekes S, Satici O, Budak T. Determination of serum hepatitis B virus DNA in chronic HBsAg carriers: clinical significance and correlation with serological markers. Turk J Gastroenterol. 2003;14:157–163
  13. Villa E, Grottola A, Trande P, Seium Y, Rebecchi AM, Dugani A, et al. Reactivation of hepatitis B virus infection induced by interferon (IFN) in HBsAg-positive, antiHCV-positive patients. Lancet. 1993;341:1413
  14. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-)infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol. 2007;45:525–574
  15. Utili R, Zampino R, Bellopede P, Marracino M, Ragone E, Adinolfi LE, et al. Dual or single hepatitis B and C virus infections in childhood cancer survivors: long-term follow-up and effect of interferon treatment. Blood. 1999;94:4046–4052
  16. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001;96:2973–2977
  17. Marrone A, Zampino R, D’Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol. 2004;41:1064–1065
  18. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–576
  19. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol. 2005;20:727–732
  20. Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2005;10:125–133
  21. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–1359
  22. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol. 2003;10:298–305
  23. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217
  24. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695
  25. Rautou PE, Asselah T, Saadoun D, Martinot M, Valla D, Marcellin P. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. Eur J Gastroenterol Hepatol. 2006;18:1019–1022
  26. Potthoff A, Deterding K, Trautwein C, Rifai K, Manns MP, Wedemeyer H. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient. Eur J Gastroenterol Hepatol. 2007;19:906–909
  27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–1520
  28. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol. 1994;75:1053–1061
  29. Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol. 1999;14:893–898
  30. Janssen HL, Lau GK. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs. Hepatology. 2005;42:1459
  31. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol. 1993;67:5823–5832
  32. Shih CM, Chen CM, Chen SY, Lee YH. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol. 1995;69:1160–1171
  33. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol. 2002;37:855–862
  34. Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34:404–410
  35. van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology. 2006;44:907–914
  36. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology. 2007;361:141–148
  37. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  38. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982

☆ A.P., H.W., W.B., T.B., S.Z., U.S., K.D., M.P.M., C.T. were investigators in several clinical trials using different interferons. They also have received research grants and lecturer fees by Schering-Plough. M.P.M. and S.Z. have served as advisory board members for Schering-Plough. W.B. is currently an employee of Boehringer Ingelheim, Germany.

PII: S0168-8278(08)00282-1

doi: 10.1016/j.jhep.2008.03.028

Journal of Hepatology
Volume 49, Issue 5 , Pages 688-694 , November 2008

Article Tools

* Image Usage & Resolution